AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%

Reuters

Oct 02

AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%

AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the PICC, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572515314"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572515314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572515314?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572515314","market":"us","top_or_hot":-1,"title":"AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the <a href=\"https://laohu8.com/S/01339\">PICC</a>, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-02 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the <a href=\"https://laohu8.com/S/01339\">PICC</a>, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL9Nqfjz:1","article_id":"2572515314","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572515314","pubTimestamp":1759399242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the PICC, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ANGO":"Angiodynamics"},"translate_title":"血管动力学报告2026财年第一季度业绩；医疗技术销售额增长26.1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":0.9},"content_text":"AngioDynamics Reports Q1 FY2026 Results; Med Tech Sales Grow 26.1%\n    \n\n        AngioDynamics reported revenue for the first quarter of fiscal 2026 of $81.7 million, compared to $78.7 million in the prior-year period. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher than in the first quarter of fiscal 2025 and 260 basis points higher than in the fourth quarter of fiscal 2025. Gross margin included $1.7 million of tariff expense. The company recorded a GAAP net loss of $10.9 million in the first quarter of fiscal 2026. Adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, compared to an adjusted net loss of $4.4 million in the first quarter of fiscal 2025. Adjusted EBITDA in the first quarter of fiscal 2026 was $2.2 million, compared to $1.4 million in the prior-year period. Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023, as well as the PICC, Midline, and tip location product portfolios divested in February 2024, and discontinued Radiofrequency and Syntrax support catheter products in February 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002437808) on October 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}